Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Advances in diabetes...combating the menace of HIV/Tuberculosis co-infection

12 Jun 06

Today's edition highlights news from Metabolex announcing the initiation of a Phase 2/3 trial of a novel insulin sensitizer, metaglidasen. In addition we discuss research published by Advanced Life Sciences who are making exciting breakthroughs moving towards the treatment of HIV Tuberculosis co-infection which has become a global catastrophe.
LeadDiscovery

Targeting Ubiquitin For Drug Discovery & Development

10 Jun 06

Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implica
Seth Fritts

Merck wins the race for HPV vaccine approval in the US...CRP inhibitor shows promise as a cardioprotective agent

09 Jun 06

Today we report on the FDA approval of Merck's HPV vaccine, the first such vaccine to be approved in the US; and a candidate treatment for various cardiovascular diseases
LeadDiscovery

Losartan, a stimulator of insulin release?

08 Jun 06

DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from blood pressure control. In addition we report on European approval of Thelin, Encysive’s candidate for the treatment of pulmonary hypertension
LeadDiscovery

Osteoarthritis: the silent burden

08 Jun 06

Osteoarthritis is the leading cause of disability in the US, and is estimated to be the eighth most common cause of disability worldwide, with around 89 million adults in the seven major markets having a form of symptomatic osteoarthritis. OA therefore offers an attractive commercial target. However, relatively low disease awareness and Cox-2s controversy have curbed the market's potential so far.
Datamontor CommentWire

More on HDAC inhibitors...Pfizer report development of new 5-HT4 receptor ligands

07 Jun 06

DailyUpdates 7th June: ASCO is finished for this year now but not before Gloucester Pharmaceuticals managed to counter yesterday’s news from Merck with clinical data on their own HDAC inhibitor. Together this means that the two most advanced HDAC inhibitors are progressing nicely towards the market and soon, we hope, cancer patients will be offered another option. Also today we report on Pfizer’s very early stage serotonin 5-HT receptor ligands, a class that is emerging from the arena of IBS to
leaddiscovery

Oncology news from ASCO plus a competitor to antibody therapeutics

05 Jun 06

(The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX vaccine for the treatment of CML. In their phase 2 trial the company reports that a complete molecular response is seen in 25% of patients whose treatment included GVAX - this compares to historical data of about 10% in patients not receivin
LeadDiscovery

Should CATIE dictate choice of antipsychotic in chronic schizophrenia?

02 Jun 06

Psychiatrists attending this year’s Annual Psychiatric Association meeting heard new findings from the controversial CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) programme. New data suggest an older typical antipsychotic drug is more cost effective and has the same cognitive benefits as newer atypical drugs. Previous results suggested the older first generation drug is equally effective and well-tolerated clinically, compared to newer atypicals but the study design was m
Olwen Glynn Owen - PharmiWeb Field Reporter

From sepsis to depression

31 May 06

DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant desvenlafaxine. Read on for more about these highlight on visit today's edition of DailyUpdates for more on these advances or any of the other 50+ items featured today
LeadDiscovery

EntreMed hoping for success with Panzem/Avastin combo

31 May 06

EntreMed has initiated a phase II trial of Panzem in combination with Genentech's Avastin in carcinoid cancer. The trial will examine how the therapy fares against potential rivals and its possible use in other tumor types. With the blockbuster Avastin possessing the potential to significantly raise the profile of Panzem, the study will prove crucial for EntreMed's lead pipeline drug candidate.
Datamonitor

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.